Angiotensin II for the emergency physician

作者：Marianne Wallis, Jonathan H. Chow, Michael E. Winters, Michael T. McCurdy · 发表于：Emergency Medicine Journal · 年份：2020 · DOI：10.1136/emermed-2019-209062 · 被引用次数：2 · 研究领域：Sepsis Diagnosis and Treatment、Electrolyte and hormonal disorders、Hemodynamic Monitoring and Therapy

Refractory hypotension is one of the most common and difficult clinical problems faced by acute care clinicians, and it poses a particularly large problem to the emergency physician when a patient in undifferentiated shock arrives in the department. Angiotensin II (Ang-2) has been previously used as a vasopressor to combat shock; the feasibility of its clinical use has been reinvigorated after approval of a human synthetic formulation of the medication by the US Food and Drug Administration in 2017 and the European Medicines Agency in 2019. A thorough literature search was completed, and in this review, we discuss the discovery and development of Ang-2, its complex mechanisms of vasoconstriction, its potential adverse effects and its potential role in clinical practice for emergency physicians.